HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (37) Citing Articles via Google Scholar Google Scholar Articles by Robben, J. H. Articles by Deen, P. M. T. Search for Related Content PubMed PubMed Citation Articles by Robben, J. H. Articles by Deen, P. M. T.

INVITED REVIEW

Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus

Department of Physiology, Nijmegen Centre for Molecular Life Sciences and Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

In the renal collecting duct, water reabsorption is regulated by the antidiuretic hormone vasopressin (AVP). Binding of this hormone to the vasopressin V2 receptor (V2R) leads to insertion of aquaporin-2 (AQP2) water channels in the apical membrane, thereby allowing water reabsorption from the pro-urine to the interstitium. The disorder nephrogenic diabetes insipidus (NDI) is characterized by the kidney's inability to concentrate pro-urine in response to AVP, which is mostly acquired due to electrolyte disturbances or lithium therapy. Alternatively, NDI is inherited in an X-linked or autosomal fashion due to mutations in the genes encoding V2R or AQP2, respectively. This review describes the current knowledge of the cell biological causes of NDI and how these defects may explain the patients' phenotypes. Also, the increased understanding of these cellular defects in NDI has opened exciting initiatives in the development of novel therapies for NDI, which are extensively discussed in this review.

osmoregulation; protein trafficking; genetic disorder; collecting duct; lithium; pharmacological chaperones

This article has been cited by other articles:

				M. Faerch, J. H. Christensen, S. Rittig, J.-O. Johansson, N. Gregersen, F. de Zegher, and T. J. Corydon Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1518 - F1525. [Abstract] [Full Text] [PDF]

				F. Jean-Alphonse, S. Perkovska, M.-C. Frantz, T. Durroux, C. Mejean, D. Morin, S. Loison, D. Bonnet, M. Hibert, B. Mouillac, et al. Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2190 - 2203. [Abstract] [Full Text] [PDF]

				C. Y Y Cheng, J. Y S Chu, and B. K C Chow Vasopressin-independent mechanisms in controlling water homeostasis J. Mol. Endocrinol., September 1, 2009; 43(3): 81 - 92. [Abstract] [Full Text] [PDF]

				J. H. Robben, M. L. A. Kortenoeven, M. Sze, C. Yae, G. Milligan, V. M. Oorschot, J. Klumperman, N. V. A. M. Knoers, and P. M. T. Deen Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists PNAS, July 21, 2009; 106(29): 12195 - 12200. [Abstract] [Full Text] [PDF]

				O. Devuyst, I. Meij, X. Jeunemaitre, P. Ronco, C. Antignac, E. I. Christensen, N. V. Knoers, E. N. Levtchenko, P. M. Deen, D. Muller, et al. EUNEFRON, the European Network for the Study of Orphan Nephropathies Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2011 - 2015. [Full Text] [PDF]

				M. Boone and P. M. T. Deen Congenital nephrogenic diabetes insipidus: what can we learn from mouse models? Exp Physiol, February 1, 2009; 94(2): 186 - 190. [Abstract] [Full Text] [PDF]

				S. Boulkroun, D. Ruffieux-Daidie, J.-J. Vitagliano, O. Poirot, R.-P. Charles, D. Lagnaz, D. Firsov, S. Kellenberger, and O. Staub Vasopressin-inducible ubiquitin-specific protease 10 increases ENaC cell surface expression by deubiquitylating and stabilizing sorting nexin 3 Am J Physiol Renal Physiol, October 1, 2008; 295(4): F889 - F900. [Abstract] [Full Text] [PDF]

				J. J. Bedford, J. P. Leader, R. Jing, L. J. Walker, J. D. Klein, J. M. Sands, and R. J. Walker Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus Am J Physiol Renal Physiol, April 1, 2008; 294(4): F812 - F820. [Abstract] [Full Text] [PDF]

				I. Schwieger, K. Lautz, E. Krause, W. Rosenthal, B. Wiesner, and R. Hermosilla Derlin-1 and p97/Valosin-Containing Protein Mediate the Endoplasmic Reticulum-Associated Degradation of Human V2 Vasopressin Receptors Mol. Pharmacol., March 1, 2008; 73(3): 697 - 708. [Abstract] [Full Text] [PDF]

				R. A. Fenton, L. Brond, S. Nielsen, and J. Praetorius Cellular and subcellular distribution of the type-2 vasopressin receptor in the kidney Am J Physiol Renal Physiol, September 1, 2007; 293(3): F748 - F760. [Abstract] [Full Text] [PDF]

				P. M. T. Deen Mouse models for congenital nephrogenic diabetes insipidus: what can we learn from them? Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1023 - 1026. [Full Text] [PDF]

				J. H. Robben, M. Sze, N. V. A. M. Knoers, and P. M. T. Deen Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus Am J Physiol Renal Physiol, January 1, 2007; 292(1): F253 - F260. [Abstract] [Full Text] [PDF]